The original press release by GW pharmaceuticals came out on February 7 (click here).
The data was also published for the 2017 ASCO conference (click here).
"Median survival in the placebo group was 369 days, and > 550 days in the CBD:THC treatment group (NS) and 1 year survival was 83% and 56% in the CBD:THC and placebo groups, respectively (p = 0.042). "
Even with the small numbers of patients (12 patients in the Sativex + TMZ group, 9 patients in the placebo + TMZ group), the difference in survival at one year still managed to achieve statistical significance.
Sativex (nabiximols) is available in Canada and Europe.